Description
This book provides new insights into how new biology, and the emergence of “translational” policies to drive the health bioeconomy, is reshaping the innovation ecosystem for new therapies. A key argument is that a broader definition of value (beyond the economic aspects) is needed to understand health innovation in the twenty-first century. James Mittra is a Senior Research Fellow and Deputy Director of the Innogen Institute, based within Science, Technology and Innovation Studies at the University of Edinburgh, UK. He is an interdisciplinary researcher who has published widely on the bioeconomy. 1. New Biology and the Foundations of a Health Bioeconomy 2. Crisis in the Pharmaceutical Industry and the Promise of New Biology 3. The ‘Broken Middle’ of Health Innovation 4. Organizational Transformations and the Value of Interdisciplinarity 5. Regulation, Policy and Governance of Advanced Therapies 6. The Role of Patients and Publics in Health Innovation 7. Rethinking Value and Expectations in the Health Bioeconomy
